Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Fluocortolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.69 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.69 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 2/20 | 0.69 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.69 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.69 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.61 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.56 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 9/20 | 0.69 |
| ▸ | AR | P10275 | 6/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluocortolone SCHEMBL21706397 | 0.99 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL3047399 | 0.99 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL11518086 | 0.99 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL19327147 | 0.99 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL11333890 | 0.99 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL13902941 | 0.99 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL11862489 | 0.99 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL4644 | 0.99 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL21852268 | 0.97 | PGR (0.68) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL3690986 | 0.96 | PGR (0.67) | PGRARADRA1ACHRM1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | claimed |
| EP-2181704-A2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1594459-B1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INT AG (CH) | 2010-02-17 | — | — | EP | claimed |
| CN-101132766-A | Tablet containing steroid hormone | LOHMANN THERAPIE SYST LTS (DE) | 2008-02-27 | — | — | CN | claimed |
| US-20060222708-A1 | Wafer comprising steroid hormones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-10-05 | — | — | US | claimed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4646217-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | Stellular Bio, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-116615210-A | Novel anuclear cells as a source for the treatment of platelet-rich plasma-dependent disorders | 血小板生源说股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20230174939-A1 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | STELLULAR BIO, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4149497-A1 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | Platelet Biogenesis, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4125947-A1 | NOVEL ANUCLEATED CELLS FOR THE TREATMENT OF DISEASES | Platelet Biogenesis, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-04 | — | — | US | disclosed |
| US-20040220153-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | COMBINATORX, INCORPORATED | 2004-11-04 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004060405-A2 | TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060346-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004030618-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | COMBINATORX, INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | CD44, SELP, EPCAM | ADRA1A 3126/4885CHRM1 1366/4885ADORA3 575/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | ADRA1A 3079/4885CHRM1 3915/4885ADORA3 1227/4885 |
| US-20040220153-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | TNF, IL5, IL6 | ADRA1A 534/4885CHRM1 2877/4885ADORA3 856/4885 |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | ADRA1A 3416/4885CHRM1 1821/4885ADORA3 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.